EndoPredict® test receives positive NICE recommendation for patients with breast cancer
Myriad Genetics announced that the UK’s National Institute for Health and Care Excellence has included EndoPredict® in its recommendations for guiding adjuvant chemotherapy decisions for people with ER-positive, HER2-negative early breast cancer and who are lymph node-negative. December 19, 2018